ClinicalTrials.gov
public full text
Public Domain
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis#918748
- Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery#911663
- Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma#1057272
- A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy#853209
- Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study#967864
Record · ID 1396775
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive